Study for development of attenuated IBV vaccine using recombinant viral vector

• Project/Area Number: 25850193
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Animal production science
• Research Institution: Nippon Institute for Biological Science
• Principal Investigator: Inayoshi Yujin 一般財団法人日本生物科学研究所, その他部局等, 研究員(移行) (70597963)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 伝染性気管支炎ウイルス / ワクチン / リバースジェネティクス / コロナウイルス / 生ワクチン / 鶏伝染性気管支炎ウイルス / 組換えウイルス / 鶏感染症

Outline of Final Research Achievements

In this study, a molecularly cloned Infectious Bronchitis Virus (IBV) of an attenuated live vaccine strain was constructed by using reverse genetic system. The cloned IBV was used as a recombinant vector platform to replace its spike protein gene with that of pathogenic IBV strains recently isolated in field. The resultant spike-recombinant clones exhibited an attenuated phenotype, as does the IBV vaccine clone, and induced a protective immunity against the pathogenic field strain used for the spike-recombination. The spike-recombination strategy using reverse genetics system holds promise for the development of live-attenuated vaccines against pathogenic IBV strains newly emerged in field.